Analyst Price Targets — STRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 12:08 am | Laura Prendergast | Stifel Nicolaus | $48.00 | $24.15 | TheFly | Sutro Biopharma initiated with a Buy at Stifel |
| June 11, 2026 11:38 am | — | Truist Financial | $50.00 | $26.09 | TheFly | Sutro Biopharma assumed with a Buy at Truist |
| May 28, 2026 7:36 am | Lukas Shumway | Barclays | $56.00 | $29.69 | StreetInsider | Barclays Starts Sutro Biopharma (STRO) at Overweight |
| May 15, 2026 10:33 am | — | Wedbush | $60.00 | $38.42 | TheFly | Sutro Biopharma upgraded to Outperform from Neutral at Wedbush |
| May 15, 2026 10:16 am | Andrew Fein | H.C. Wainwright | $50.00 | $38.42 | TheFly | Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright |
| May 15, 2026 10:05 am | — | Leerink Partners | $43.00 | $38.42 | TheFly | Sutro Biopharma price target raised to $43 from $38 at Leerink |
| April 30, 2026 9:14 am | — | Mizuho Securities | $50.00 | $35.39 | TheFly | Sutro Biopharma initiated with an Outperform at Mizuho |
| March 14, 2025 1:19 pm | — | Piper Sandler | $20.00 | $8.10 | TheFly | Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler |
| October 11, 2024 7:01 am | Tazeen Ahmad | Bank of America Securities | $120.00 | $36.05 | StreetInsider | BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO) |
| October 11, 2024 6:36 am | Andrew Fein | H.C. Wainwright | $120.00 | $36.10 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO) |
Latest News for STRO
Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Profitability This table compares Sutro Biopharma and
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.
– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6…
Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money fast, including a dramatic target cut on Trade Desk and a fresh Buy on SpaceX as markets brace for next week's inflation data.
Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 42.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,069,519 shares of the company's stock after purchasing an additional 321,137 shares during the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STRO.
U.S. House Trading
No House trades found for STRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.